GB Sciences Inc (GBLX)

[snifferpup]

GB Sciences, CEO, John Poss, Joins Everett Jolly on Uptick Newswire's "Stock Day" Podcast

9:00 am ET April 19, 2018 (Globe Newswire) Print


GB Sciences, Inc. (OTCQB:GBLX) ("the "Company"), today announced CEO, John Poss, returned to Uptick Newswire's "Stock Day" podcast with Everett Jolly for an operational update.

"GB Sciences is a cannabis based medical research company," said Jolly. "It has built a strong commercial brand, which helps the Company fund research. John Poss joins us today to discuss the many things that have come to pass in recent months."

The Company is currently in 30-day due diligence period for the acquisition of Nevada Pure.

Additionally, GB Sciences is planning to file an Exploratory IND in order to initiate an in-human trial for a Parkinson's therapy.

"We are excited for what the year will bring," said Poss. "We hope to have FDA approval for our Parkinson's trail by December of this year. The acquisition of Nevada Pure would bring about $16 million to our bottom line and we have until April 26 to finalize the purchase; in all we are excited about 2018."

To listen to the full interview please click here to the following link:

https://upticknewswire.com/featured-interview-ceo-john-poss-of-gb-sciences-inc-otcqb-gblx-4/